【摘要】 近年来，B细胞淋巴瘤药物治疗取得显著进展。在一线治疗中，基于免疫治疗和化疗的新型联合方案[包括R-CHOP+X方案、布鲁顿酪氨酸激酶（BTK）抑制剂、抗体药物偶联物（ADC）及双特异性抗体]显著改善患者生存结局；而在复发/难治性B细胞淋巴瘤治疗领域，双特异性抗体、嵌合抗原受体T细胞（CAR-T）疗法及新一代靶向药物（如BTK抑制剂和Bcl-2抑制剂）展现出深度持久的缓解潜力。本文系统综述了弥漫大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）、套细胞淋巴瘤（MCL）、慢性淋巴细胞白血病（CLL）等不同亚型的B细胞淋巴瘤基于一线与复发/难治分层的最新治疗进展，重点探讨了靶向治疗、免疫治疗及细胞治疗等突破性治疗策略。更多还原

【Abstract】 In recent years, remarkable advances have been achieved in the pharmacological management of B-cell lymphomas. In frontline therapy, novel immunochemotherapy-based combinations, including R-CHOP + X regimens, Bruton’s tyrosine kinase(BTK) inhibitors, antibody-drug conjugates(ADCs), and bispecific antibodies, have significantly improved survival outcomes. For relapsed/refractory(R/R) B-cell lymphomas, bispecific antibodies, chimeric antigen receptor T-cell(CAR-T) therapies, and next-generation targeted agents(e.g., BTK and BCL-2 inhibitors) have demonstrated potential for deep and durable responses. This review systematically summarizes the latest therapeutic progress stratified by frontline and R/R settings across major B-cell lymphoma subtypes: diffuse large B-cell lymphoma(DLBCL), follicular lymphoma(FL), mantle cell lymphoma(MCL), and chronic lymphocytic leukemia(CLL). Emphasis is placed on therapeutic breakthroughs in targeted therapy, immunotherapy, and cellular therapy.更多还原